Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas (EPL)
This study has been completed.
Sponsor:
Queensland Institute of Medical Research
Collaborators:
The Atlantic Philanthropies
Australian Department of Industry, Tourism and Resources
British Society for Haematology
National Health and Medical Research Council, Australia
Information provided by (Responsible Party):
Maher Gandhi, Queensland Institute of Medical Research
ClinicalTrials.gov Identifier:
NCT00779337
First received: October 22, 2008
Last updated: May 21, 2012
Last verified: May 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Study Completion Date: | May 2012 |
| Primary Completion Date: | January 2012 (Final data collection date for primary outcome measure) |